Literature DB >> 18575827

Late immune recovery in children treated for malignant diseases.

Gabor T Kovacs1, Olga Barany, Barbara Schlick, Monika Csoka, Judit Gado, Andrea Ponyi, Judit Müller, Julia Nemeth, Peter Hauser, Daniel J Erdelyi.   

Abstract

In this study we analyzed the recovery of the immune system in children after completion of the therapy. We analysed 88 children (51 boys, 37 girls, mean age at diagnosis: 7.8 years) receiving chemotherapy for malignant diseases (43 acute lymphoblastic leukemia, 15 lymphoma, 20 bone tumor, ten other solid tumors). Serum immunoglobulin levels (Ig), natural killer activity (NK), antibody-dependent cellular cytotoxicity (ADCC) and T and B cell proliferation were determined 1 year after cessation of therapy. The mean levels of Ig were in the normal range at a mean of 13 months after chemotherapy (IgG: 11.2 +/- 3.3, IgA: 1.6 +/- 0.9, IgM: 1.0 +/- 0.5 g/l), however in the leukemic patients serum IgG was below the lower limit of the normal range in 3/43 (7.0%) cases, serum IgA was low in 5/43 (11.6%) and serum IgM was decreased in 4/43 (9.3%) cases. In the solid tumor patients IgG values were within the normal range and only 2-2/45 children had lower values for IgA and IgM (4.4%). NK activity decreased in 7/43 (16.3%) leukemic patients, and in 3/45 (6.7%) solid tumor patients, ADCC decreased in 8/43 (18.6%) and 3/45 (6.7%), respectively (p < 0.001). B-cell blastic transformation was decreased in 3/43 (7%) leukemic patients and in 4/45 (8.9%) solid tumor patients. At the same time T-cell blastic transformation was altered in 5/43 (11.6%) and in 4/45 (8.9%) cases, respectively. Leukemic patients had significantly more infections during the first year after chemotherapy than solid tumor patients (1.60 +/- 1.18 vs 0.96 +/- 1.14; p = 0.011). No significant correlations could be found between the investigated immune parameters and the number and severity of infections. It is concluded, that cytotoxic therapy can lead to long-term depression of the immune system, first of all in leukemic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575827     DOI: 10.1007/s12253-008-9073-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal study.

Authors:  B Argüelles; V Barrios; J Pozo; M T Muñoz; J Argente
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

Review 2.  Long-term survivors of childhood cancer: the late effects of therapy.

Authors:  C L Schwartz
Journal:  Oncologist       Date:  1999

3.  Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation.

Authors:  A Lando; K Holm; K Nysom; U Feldt-Rasmussen; J H Petersen; J Müller
Journal:  Clin Endocrinol (Oxf)       Date:  2001-07       Impact factor: 3.478

4.  Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers.

Authors:  S K Jackson; J Parton; G Shortland; J M Stark; E N Thompson
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

Review 5.  Immune reconstitution in pediatric stem-cell transplantation.

Authors:  J J Auletta; V L Fisher
Journal:  Front Biosci       Date:  2001-08-01

6.  Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children.

Authors:  F Locatelli; R Maccario; P Comoli; F Bertolini; G Giorgiani; D Montagna; F Bonetti; P De Stefano; G Rondini; G Sirchia; F Severi
Journal:  Bone Marrow Transplant       Date:  1996-12       Impact factor: 5.483

7.  Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors.

Authors:  S Alanko; T T Salmi; T T Pelliniemi
Journal:  Med Pediatr Oncol       Date:  1995-06

8.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors.

Authors:  K Kalwak; I Mosoń; J Cwian; E Gorczyńska; J Toporski; D Turkiewicz; E Latos-Grazyńska; A Chybicka
Journal:  Transplant Proc       Date:  2003-06       Impact factor: 1.066

10.  Survival rates of childhood cancer patients in Osaka, Japan.

Authors:  Wakiko Ajiki; Hideaki Tsukuma; Akira Oshima
Journal:  Jpn J Clin Oncol       Date:  2004-01       Impact factor: 3.019

View more
  3 in total

1.  Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies: a study on the safety and immunogenicity efficacy.

Authors:  Pengfei Deng; Tian Yang; Hua Zhang; Fen Zhou; Caoyi Xue; Yi Fei; Yijin Gao
Journal:  Hum Vaccin Immunother       Date:  2021-08-17       Impact factor: 4.526

2.  Immune reconstitution in children following chemotherapy for acute leukemia.

Authors:  Anthony P Williams; Jessica Bate; Rachael Brooks; Julia Chisholm; Stuart C Clarke; Elizabeth Dixon; Saul N Faust; Angeliki Galanopoulou; Paul T Heath; Thomas Maishman; Susan Mapstone; Soonie R Patel; Ajay Vora; Sam A Wilding; Juliet C Gray
Journal:  EJHaem       Date:  2020-06-10

3.  HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors.

Authors:  Detchvijitr Suwanpakdee; Wattanee Taweesith; Chanchai Traivaree; Piya Rujkijyanont
Journal:  Glob Pediatr Health       Date:  2021-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.